Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...